Visual Abstract

Insulin pumps and CGM devices can help youth with T1D achieve better glycemic control and alleviate self-care burden. However, not all youth want to use such devices. We compared psychosocial characteristics of teens with T1D and their parents/caregivers according to teen pump use vs. non-use as well as teen CGM use vs. non-use. At baseline, teens/parents completed psychosocial surveys assessing teen depressive symptoms [CESD], disordered eating behaviors, diabetes-specific family conflict, parent involvement in diabetes care, teen self-care, diabetes burden (PAID-Ped/PR), quality of life, and major life events. Diabetes treatment data were collected by interview and EHR review every 3 months for 18 months. Teens using/starting pump or CGM at all/most visits were considered pump users or CGM users, respectively. Chi-square and t-tests compared characteristics of device (pump, CGM) users with non-users. The sample comprised 301 teens aged 13-17 with T1D (41% male); mean age was15.0±1.3 years, T1D duration 6.5±3.7 years, and A1c 8.5±1.1%. Neither age, sex, nor T1D duration was related to device use. CGM and pump non-users had less favorable survey scores than device users for many psychosocial characteristics (Table). Identifying teens with less favorable psychosocial factors may help target those at risk for device non-use, allowing timely intervention and support by clinicians when initiating diabetes technologies.


C. Chen: None. L. J. Tinsley: None. L. K. Volkening: None. B. Anderson: None. L. M. Laffel: Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Dexcom, Inc., Dompe, Insulogic LLC, Janssen Pharmaceuticals, Inc., Laxmi Therapeutic Devices, LifeScan, Lilly Diabetes, Medtronic, Provention Bio, Inc.


National Institutes of Health (R01DK095273, T32DK007260, P30DK036836); JDRF (2-SRA-2014-253-M-B)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at